Akiyama, Hiroki http://orcid.org/0000-0003-2627-1055
Zhao, Ran http://orcid.org/0000-0003-3390-5343
Ostermann, Lauren B. http://orcid.org/0000-0002-3330-2174
Li, Ziyi
Tcheng, Matthew
Yazdani, Samar J.
Moayed, Arman
Pryor, Malcolm L. II
Slngh, Sandeep http://orcid.org/0000-0001-8780-5124
Baran, Natalia http://orcid.org/0000-0003-0618-4798
Ayoub, Edward http://orcid.org/0000-0003-1321-0114
Nishida, Yuki
Mak, Po Yee
Ruvolo, Vivian R. http://orcid.org/0000-0003-4363-7258
Carter, Bing Z. http://orcid.org/0000-0003-0076-0889
Schimmer, Aaron D. http://orcid.org/0000-0003-4023-3899
Andreeff, Michael http://orcid.org/0000-0002-1144-1958
Ishizawa, Jo http://orcid.org/0000-0001-8566-7370
Article History
Received: 5 March 2023
Revised: 2 December 2023
Accepted: 8 December 2023
First Online: 26 December 2023
Change Date: 8 March 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41375-024-02202-0
Competing interests
: MA is a stockholder of Chimerix. JI, MA, and ADS have filed invention disclosure forms related to the use of imipridones in cancers. ADS has received research funding from Takeda Pharmaceuticals, BMS and Medivir AB, and consulting fees/honorarium from Takeda, Novartis, Jazz, and Otsuka Pharmaceuticals. ADS is named on a patent application for the use of DNT cells to treat AML. ADS is a member of the Medical and Scientific Advisory Board of the Leukemia and Lymphoma Society of Canada.
: The mouse studies were performed following the guidelines approved by the Institutional Animal Care and Use Committees at MD Anderson Cancer Center. Primary samples were obtained from AML patients and hematopoietic stem cell donors after acquiring written informed consent following MD Anderson Cancer Center Institutional Review Board protocol and in accordance with the Declaration of Helsinki.